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Abstract 
Background  
Insulin resistance predisposes to cardiometabolic disorders, which are commonly comorbid 
with schizophrenia, and are the key contributors to the significant excess mortality in 
schizophrenia. Mechanisms for the comorbidity remain unclear, but observational studies 
have implicated inflammation in both schizophrenia and cardiometabolic disorders 
separately. We aimed to examine whether there is genetic evidence that insulin resistance and 
seven related cardiometabolic traits may be causally associated with schizophrenia, and 
whether evidence supports inflammation as a common mechanism for cardiometabolic 
disorders and schizophrenia. 
Methods and Findings 
We used summary data from genome-wide association studies of mostly European adults 
from large consortia (Meta-Analyses of Glucose and Insulin-related traits Consortium 
(MAGIC) featuring up to 108,557 participants; Diabetes Genetics Replication And Meta-
analysis (DIAGRAM) featuring up to 435,387 participants; Global Lipids Genetics 
Consortium (GLGC) featuring up to 173,082 participants; Genetic Investigation of 
Anthropometric Traits (GIANT) featuring up to 339,224 participants; Psychiatric Genomics 
Consortium (PGC) featuring up to 105,318 participants; Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) consortium featuring up to 204,402 
participants). We conducted two-sample uni- and multi-variable Mendelian randomization 
(MR) analysis to test whether: (i) ten cardiometabolic traits (fasting insulin, high-density 
lipoprotein and triglycerides representing an IR phenotype, and seven related cardiometabolic 
traits: low-density lipoprotein, fasting plasma glucose, glycated haemoglobin, leptin, body 
mass index, glucose tolerance and type 2 diabetes) could be causally associated with 
schizophrenia; (ii) inflammation could be a shared mechanism for these phenotypes. We 
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conducted a detailed set of sensitivity analyses to test the assumptions for a valid MR 
analysis. We did not find statistically significant evidence in support of a causal relationship 
between cardiometabolic traits and schizophrenia, or vice versa. However, we report that a 
genetically-predicted inflammation-related insulin resistance phenotype (raised fasting 
insulin (Inverse Variance Weighted (IVW) OR=2.76, 95% C.I, 1.08-7.11, Holm-Bonferroni 
corrected p-value (p)=0.040), raised triglycerides (IVW OR=2.86, 95% C.I., 1.23-6.66, p-
=0.035), lower high-density lipoprotein (IVW OR=0.52, 95% C.I., 0.33-0.82; p=0.030)) was 
associated with schizophrenia. Evidence for these associations attenuated completely in 
multi-variable MR analyses after adjusting for C-reactive protein (CRP), an archetypal 
inflammatory marker: (fasting insulin IVW OR=0.95, 95% C.I, 0.55-1.62, p=0.645), 
triglycerides (IVW OR=0.79, 95% C.I., 0.58-1.21, p=0.203) and lower high-density 
lipoprotein (IVW OR=1.48, 95% C.I., 0.66-3.33; p=0.340), suggesting that the associations 
could be fully explained by inflammation. One potential limitation of the study is that the full 
range of gene-products from the genetic variants we used as proxies for the exposures is 
unknown, and so we are unable to comment on potential biological mechanisms of 
association other than inflammation, which may also be relevant.  
 
Conclusions 
Our findings support a role for inflammation as a common cause for insulin resistance and 
schizophrenia, which may at least partly explain why the traits commonly co-occur in clinical 
practice. Inflammation and immune pathways may represent novel therapeutic targets for the 
prevention or treatment of schizophrenia and comorbid insulin resistance. Future work is 
needed to understand how inflammation may contribute to the risk of schizophrenia and 
insulin resistance. 
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Author Summary 
Why was this study done? 
• Cardiometabolic disorders such as diabetes are up to 30% more common in people 
with schizophrenia than in the general population, and are amongst the predominant 
causes of a 10-15 year shortened life-expectancy in people with schizophrenia. 
• Insulin resistance, a precursor to diabetes, is sometimes detectable in young adults 
suffering their first episode of psychosis, which suggests that chronic lifestyle and 
clinical factors, such as smoking, physical inactivity and medication side effects, may 
not fully explain the comorbidity. 
• Inflammation has been consistently associated with schizophrenia and 
cardiometabolic disorders, and so could be a common mechanism for schizophrenia 
and cardiometabolic disorders. This could help to at least in part explain why people 
who have schizophrenia also have higher rates of cardiometabolic disorders, over and 
above the commonly attributed lifestyle/clinical factors. 
 
What did the researchers do and find? 
• To examine whether insulin resistance and seven related cardiometabolic traits 
causally influence schizophrenia risk or vice versa, we conducted bi-directional, two-
sample, uni- and multi-variable Mendelian Randomization (MR) analyses. The MR 
approach uses genetic variants as proxies for modifiable exposures to untangle the 
problems of reverse causation and unmeasured confounding. 
• To test a hypothesis that inflammation may be a common mechanism for 
schizophrenia and cardiometabolic disorders, we also examined a subset of genetic 
variants which were associated with inflammation as well as the cardiometabolic trait, 
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and used multi-variable MR as a sensitivity analysis to adjust for C-reactive protein 
(CRP), an archetypal inflammatory marker, as a general downstream marker of 
systemic inflammation. 
• After correction for multiple testing, overall, there was no significant evidence in 
support of a causal relationship between cardiometabolic traits and schizophrenia, or 
vice versa. However, we found evidence that supports a causal relationship of an 
inflammation-related insulin resistance phenotype (comprising of raised fasting 
insulin, raised triglycerides and decreased high-density lipoprotein) with 
schizophrenia. 
• Evidence for the association of an inflammation-related insulin resistance phenotype 
with schizophrenia attenuated fully in multi-variable MR analysis after adjusting for 
CRP, suggesting that these associations may be underpinned by inflammation. 
What do these findings mean?  
• These results suggest that cardiometabolic traits are unlikely to have a causal role in 
the pathogenesis of schizophrenia, or vice versa. However, our results suggest that 
inflammation is related to the risk of both schizophrenia and insulin resistance, which 
may at least partly explain why they commonly occur in clinical practice. 
• Treating or preventing inflammation may be a putative therapeutic option for 
prevention and/or treatment of both schizophrenia and comorbid insulin resistance. 
• In the future, more research is needed to understand the biological mechanisms 
underpinning how inflammation may increase the risk of schizophrenia and insulin 
resistance.  
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Introduction 
Schizophrenia is a complex behavioural and cognitive syndrome characterized primarily by 
disruptions to perception and cognition [1]. It has a lifetime prevalence of around 0.4% [2], 
but carries a significant global disease burden [3]. Cardiometabolic disorders are up to 30% 
more common in schizophrenia than the general population [4] and are the leading 
contributors to premature death in these patients [5]. Their increased prevalence in 
schizophrenia is commonly attributed to the adverse effects of antipsychotic medications [6], 
or lifestyle factors such as physical inactivity and a poor diet [7], but this is unlikely to be the 
whole story. Whilst the aforementioned factors contribute cumulative risk over time [8], 
recent meta-analyses of case-control studies suggest that a phenotype of raised fasting 
insulin, raised triglycerides and low high-density lipoprotein cholesterol (HDL), indicative of 
insulin resistance (IR) [9-11], is associated with relatively young antipsychotic-naïve patients 
with first-episode psychosis (FEP) [12, 13], and, cross-sectionally, with psychotic symptoms 
in young adults [14]. Therefore, IR, which is a significant risk factor for type 2 diabetes 
mellitus (T2DM) and obesity, might be causally related to, or share pathophysiologic 
mechanisms with schizophrenia.  
The majority of existing research in the field is cross-sectional, and therefore cannot confirm 
whether cardiometabolic disorders are a cause or consequence of illness (i.e., reverse 
causality). For example, one longitudinal study found no evidence for an association between 
IR in childhood and risk of psychosis in late adolescence [14]. Additionally, whilst previous 
studies have adjusted for a number of potential confounders, residual confounding, which is a 
limitation of both cross-sectional and longitudinal research, could still be relevant. Mendelian 
randomization (MR) analysis can address these limitations by using genetic variants inherited 
randomly at conception as unconfounded proxies of a modifiable exposure, to examine 
whether the exposure may have a causal effect on a disease outcome [15]. MR studies of 
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cardiometabolic traits and schizophrenia are limited, have focused on a very limited set of 
cardiometabolic exposures, and have reported mixed findings [16, 17]. To our knowledge, 
MR studies examining associations between a wide range of cardiometabolic traits and 
schizophrenia are lacking. Such studies may help to identify common potentially causal risk 
factors and pathophysiologic mechanisms for these physical and psychiatric illnesses.  
Inflammation could be pathophysiologically related to cardiometabolic disorders and 
schizophrenia. Higher levels of circulating inflammatory markers have been associated with 
both psychosis and cardiometabolic disorders, both cross-sectionally and longitudinally [18-
20]. MR studies have reported potential causal associations between inflammation, 
particularly C-reactive protein (CRP) and interleukin-6 (IL-6), and schizophrenia [21, 22]. 
CRP and IL-6 are also implicated in pathogenesis of IR [23], and may exaggerate the effects 
of IR on psychosis-risk in young adults [14]. However, to our knowledge, no MR studies 
have examined whether inflammation could be pathophysiologically related to IR and 
schizophrenia, for example via mediating or common-causal mechanisms. 
Therefore, we have conducted a study to examine evidence in support of four scenarios 
regarding the potential relationships between inflammation, IR and schizophrenia: a) 
inflammation is a common cause (confounder) between IR and schizophrenia; b) IR mediates 
an association between inflammation and schizophrenia; or vice versa: c) inflammation is a 
common cause (confounder) between schizophrenia and IR; d) schizophrenia mediates an 
association between inflammation and IR. See S1 Methods for directed acyclic graphs 
(DAGs) illustrating the proposed mechanisms. 
First, we carried out MR analyses to test whether 10 cardiometabolic traits related to IR 
(fasting insulin (FI); triglycerides, high-density lipoprotein (HDL); low-density lipoprotein 
(LDL); fasting plasma glucose (FPG); body mass index (BMI); glucose tolerance; leptin, 
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glycated haemoglobin (HbA1C); and type 2 diabetes mellitus (T2DM)) could be causally 
associated with schizophrenia. To test the direction of association, we used genetically 
predicted levels of cardiometabolic traits as exposures and schizophrenia as the outcome, and 
vice versa. Next, we examined whether inflammation could be a shared mechanism linking 
IR and schizophrenia using MR analyses including genetic variants for each cardiometabolic 
trait that were also associated with a marker of inflammation at genome-wide level. Finally, 
we used multi-variable MR (MVMR) analysis to control for genetic associations of 
cardiometabolic traits with CRP, an archetypal general inflammatory marker which we used 
as a general measure for systemic inflammation. 
 
Methods 
Selection of Genetic Variants Related to Cardiometabolic Traits and Schizophrenia 
For fasting insulin, triglycerides and HDL, we used a set of 53 single nucleotide 
polymorphisms (SNPs) reported to be associated with all three traits, representative of an IR 
phenotype, from a recent meta genome-wide association study (GWAS) of 188,577 European 
adults which adjusted for BMI [11]. Summary statistics for genome-wide significant SNPs 
were obtained for six related continuous (FPG, HbA1C, LDL, BMI, leptin, glucose tolerance) 
and one binary (T2DM) cardiometabolic traits from recent large GWAS (S2-10 Methods). 
We obtained summary statistics for schizophrenia from a recent GWAS from the Psychiatric 
Genomics Consortium (PGC) [24] based on 40,675 cases and 64,643 European controls. The 
degree of sample overlap between exposure and outcome samples was likely to be low since 
the data were obtained from different consortia [25].  
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Ethics Statement 
Our study was a secondary analysis of the above publicly-available data. Informed consent 
was sought for all participants per the original GWAS protocols, and all ethical approvals for 
the GWAS were obtained by original GWAS authors.  
 
Statistical Analysis 
The analysis plan was prospectively conceived by the authors in 2019 but was not formally 
deposited in a repository or database. All described analyses were planned except the MVMR 
sensitivity analysis including CRP (see below), which was conceived in light of the findings 
from the primary analysis, to further test whether inflammation may be responsible for the 
results. We obtained summary-level data (SNP rs number; β-coefficient or log odds ratio; 
standard errors or 95% confidence intervals; effect allele; other allele; p-value; effect allele 
frequency; sample size; number of cases/controls) from each GWAS. Where a specific 
instrument SNP was not available in the outcome dataset, we located proxy SNPs using 
linkage disequilibrium (LD) tagging (r2>0.8) via LDlink [26]. Alleles were harmonised based 
on matching alleles and the resulting instruments were clumped for LD to ensure 
independence (10,000kb pairs apart, r2<0.001). In the event of palindromic SNPs, the forward 
strand was inferred where possible using allele frequency information. We performed 
bidirectional analysis (i.e. with schizophrenia as exposure and cardiometabolic traits as 
outcomes) to examine direction of association. Statistical analysis was conducted using the 
TwoSampleMR package (v0.5.4) [27] for R [28] . Our primary MR analysis method was 
inverse variance weighted (IVW) regression. We also conducted weighted median and MR-
Egger regression analysis (S11 Methods). For the binary outcome of schizophrenia, the 
estimates for continuous exposures (FI, HDL, triglycerides, LDL; FPG; BMI; HbA1C; 
glucose tolerance, leptin) represent log-odds ratios converted into odds ratios (ORs), 
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representing the increase in risk of schizophrenia per standard deviation (SD) of exposure, 
and 95% confidence intervals (C.I.s). For binary exposures (T2DM), the estimates represent 
the OR for schizophrenia per unit increase in the log-odds of T2DM. For continuous 
cardiometabolic outcomes, β-coefficients represent the SD increase in exposure per unit 
increase in the log-odds of schizophrenia, with standard errors (SEs).  
We performed several sensitivity analyses to check the validity of our results. Heterogeneity 
among SNPs included in each analysis was examined using the Cochran’s Q test. We 
checked for horizontal pleiotropy using the MR Egger regression intercept alongside a more 
recent and robust method to detect horizontal pleiotropy and outliers, ‘MR pleiotropy residual 
sum and outlier’ (MR-PRESSO) [29]. Using MR-PRESSO, we used the global test to 
examine for horizontal pleiotropy, and where evident, used the method to correct the IVW-
estimate via outlier removal (S11 Methods). We examined for measurement error in SNP-
exposure associations using the I2GX statistic [30]. This study is reported as per the 
Strengthening the Reporting of Mendelian randomization studies (STROBE-MR) guideline 
[31] (S1 Checklist) and The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement [32] (S2 Checklist). 
 
Analysis using Inflammation-Related SNPs 
Next, we repeated MR analysis using only inflammation-related SNPs for each 
cardiometabolic risk factor as an instrumental variable for the outcome of schizophrenia. We 
did this to test the hypothesis that these SNPs may represent a mechanism involving 
inflammation. This could be via, for example, a common causal basis (Panel A in S1 
Methods) or via vertical (mediating) pleiotropy [27] (Panel B in S1 Methods).  We used 
Phenoscanner v2 [33] to examine each SNP associated with each cardiometabolic risk factor, 
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to identify SNPs that were also associated (at genome-wide level; p<5×10-8 to maximise 
specificity) with a measure of inflammation, defined as blood concentration/count of 
cytokines (such as chemokines, interferons, interleukins, lymphokines, or tumour necrosis 
factors), acute phase proteins (e.g., CRP), or immune cells (e.g., neutrophils, lymphocytes) 
(S12-17 Methods). No inflammation-related SNPs were identified for glucose tolerance or 
leptin. 
Using the same method, we identified inflammation-related schizophrenia SNPs (S18 
Methods) and used them as instrumental variables in MR analysis examining cardiometabolic 
traits as outcomes. 
 
Sensitivity Analysis - Adjustment for Inflammation  
As a post-hoc sensitivity analysis to estimate whether any associations evident above may be 
explained by inflammation, we carried out MVMR analysis [34, 35] using the 53 SNPs for 
fasting insulin, triglycerides and HDL, representative of IR an phenotype, as exposures with 
schizophrenia as the outcome, after conditioning on the associations of these 53 SNPs with 
CRP. We chose CRP because it is a widely used downstream measure of systemic 
inflammation, and publicly available data from large-scale GWAS for CRP are available. 
Summary statistics for CRP were obtained from a recent large GWAS based on 204,402 
participants [36]. For CRP as an exposure in MVMR, we used all independent (10,000kb 
pairs apart, r2<0.001) SNPs reported to be conditionally associated with CRP (p<10-5) and 
located within the CRP coding region (S19 Methods).  
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Correction for Multiple Testing 
Statistical significance was estimated using the Holm-Bonferroni correction method [37], 
correcting for the number of exposures tested at each stage of analysis. 
 
Results 
MR Analyses using All Genetic Variants Associated with IR and Other 
Cardiometabolic Traits 
We did not find statistically significant evidence for associations between genetically-
predicted levels of triglycerides and HDL with schizophrenia, since estimates were 
inconsistent across MR methods and did not survive correction for multiple testing (weighted 
median OR for triglycerides=1.25; 95% C.I., 1.04-1.50; corrected p=0.180); weighted median 
OR for HDL=0.80; 95% C.I., 0.66-0.97; corrected p=0.180). We also found weak evidence 
for an association between genetically-predicted leptin levels and schizophrenia, but the 
evidence did not survive correction for multiple testing (IVW OR=2.54; 95% CI, 1.02-6.31; 
corrected p=0.440). We did not find any evidence for associations of genetically-predicted 
levels of any other cardiometabolic risk factor and schizophrenia using any MR method 
(Table 1). 
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Table 1: MR Analyses of Cardiometabolic Traits and Schizophrenia using All SNPs 
HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein; 
IVW=inverse variance weighted regression; SNPs=single nucleotide polymorphisms 
aNumber of SNPs remaining after clumping for independence 
b Each analysis method (IVW, Weighted Median and MR Egger) corrected using the Holm-
Bonferroni method for 10 cardiometabolic markers 
Estimates represent ORs for schizophrenia per SD increase in exposure (per unit-increase in log-odds 
of exposure for T2DM)
Risk Factor SNPs, 
No.a 
Method 
 
Odds Ratio (95% C.I.) p-value Corrected p-
valueb 
Fasting Insulin 46 IVW 0.85 (0.64-1.10) 0.219 1.000 
  Weighted Median 0.94 (0.71-1.23) 0.631 1.000 
  MR Egger 1.63 (0.76-3.48) 0.210 1.000 
Triglycerides 46 IVW 0.94 (0.77-1.15) 0.565 1.000 
  Weighted Median 1.25 (1.04-1.50) 0.018 0.180 
  MR Egger 1.22 (0.90-1.66) 0.202 1.000 
HDL 46 IVW 1.06 (0.88-1.27) 0.560 1.000 
  Weighted Median 0.80 (0.66-0.97) 0.020 0.180 
  MR Egger 0.79 (0.59-1.08) 0.142 1.000 
Fasting Plasma Glucose 18 IVW 1.07 (0.87-1.31) 0.522 1.000 
  Weighted Median 1.01 (0.84-1.23) 0.887 1.000 
  MR Egger 1.13 (0.74-1.74) 0.584 1.000 
Type 2 Diabetes Mellitus 89 IVW 0.93 (0.78-1.12) 0.470 1.000 
  Weighted Median 0.93 (0.79-1.09) 0.375 1.000 
  MR Egger 1.03 (0.65-1.62) 0.895 1.000 
Body Mass Index 83 IVW 1.11 (0.98-1.24) 0.060 0.540 
  Weighted Median 1.10 (0.99-1.23) 0.071 0.568 
  MR Egger 1.22 (0.95-1.56) 0.128 1.000 
HbA1C 44 IVW 1.01 (0.76-1.33) 0.800 1.000 
  Weighted Median 1.12 (0.84-1.50) 0.459 1.000 
  MR Egger 1.32 (0.76-1.32) 0.294 1.000 
Glucose Tolerance 7 IVW 0.98 (0.85-1.14) 0.800 1.000 
  Weighted Median 1.10 (0.87-1.15) 0.993 1.000 
  MR Egger 1.85 (0.95-3.32) 0.094 0.846 
LDL 74 IVW 0.99 (0.93-1.05) 0.679 1.000 
  Weighted Median 0.97 (0.90-1.03) 0.322 1.000 
  MR Egger 0.98 (0.90-1.07) 0.692 1.000 
Leptin 4 IVW 2.54 (1.02-6.31) 0.044 0.440 
  Weighted Median 1.98 (0.93-4.21) 0.076 0.568 
  MR Egger 3.13 (0.71-7.23) 0.215 1.000 
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MR Analyses using Inflammation-Related Genetic Variants for IR and Other 
Cardiometabolic Traits 
After testing only inflammatory-related variants for cardiometabolic traits, we found 
consistent evidence across several MR methods for associations of inflammation-related 
genetically-predicted fasting insulin (IVW OR=2.76; 95% C.I., 1.08-7.11; corrected 
p=0.040), triglycerides (IVW OR=2.86; 95% C.I., 1.23-6.66; corrected p=0.035), and HDL 
(IVW OR=0.52; 95% CI, 0.33-0.82; corrected p=0.030) with schizophrenia (Table 2; Fig 1 & 
Fig 2).  
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Table 2: MR Analyses of Inflammatory-Related Cardiometabolic SNPs and 
Schizophrenia 
HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein; 
IVW=inverse variance weighted regression; SNPs=single nucleotide polymorphisms 
a Each analysis method (IVW, Weighted Median and MR Egger) corrected using the Holm-
Bonferroni method for 7 cardiometabolic markers 
Estimates represent ORs for schizophrenia per SD increase in exposure (per unit-increase in log-odds 
of exposure for T2DM 
 
Fig 1: MR Analyses Testing Associations between Insulin Resistance Phenotypes 
(Fasting Insulin (A), Triglycerides (B) and HDL (C)) and Schizophrenia, Highlighting 
Inflammation-Related SNPs. 
Points in plots represent the association of the 53 insulin-resistance single nucleotide 
polymorphisms (SNPs) and their association with schizophrenia (Y axis) and the exposure (X 
axis). SNPs in purple represent inflammatory-related SNPs. SNPs in green represent non-
inflammatory SNPs. Whiskers represent SNP standard errors. Lines on plot represent inverse-
variance weighted regression of non-inflammatory SNPs (green) and inflammatory-related 
SNPs (purple).  
 
 
Risk Factor SNPs, 
No. 
Method Odds Ratio (95% 
C.I.) 
p-value Corrected 
p-valuea 
Fasting Insulin  5 IVW 2.76 (1.08-7.11) 0.010 0.040 
  Weighted Median 2.76 (1.31-5.82) 0.008 0.040 
  MR Egger 3.63 (0.41-31.98) 0.329 1.000 
Triglycerides 5 IVW 2.86 (1.23-6.66) 0.007 0.035 
  Weighted Median 2.90 (1.36-6.17) 0.015 0.060 
  MR Egger 1.31 (0.85-2.02) 0.251 1.000 
HDL  4 IVW 0.52 (0.33-0.82) 0.005 0.030 
  Weighted Median 0.56 (0.37-0.83) 0.006 0.036 
  MR Egger 0.42 (0.18-1.03) 0.153 0.918 
Fasting Plasma Glucose 2 IVW 1.53 (0.39-5.97) 0.537 0.537 
Type 2 Diabetes Mellitus 7 IVW 0.94 (0.59-1.48) 0.776 1.000 
  Weighted Median 1.05 (0.26-4.32) 0.941 1.000 
  MR Egger 1.40 (0.32-6.08) 0.668 1.000 
HbA1C 7 IVW 1.20 (0.67-2.13) 0.546 1.000 
  Weighted Median 0.93 (0.46-1.85) 0.832 1.000 
  MR Egger 1.68 (0.39-7.21) 0.508 1.000 
Body Mass Index 6 IVW  1.35 (0.88-2.08) 0.169 0.338 
  Weighted Median 1.16 (0.80-1.69) 0.425 0.425 
  MR Egger 0.68 (0.35-1.34) 0.383 1.000 
LDL 13 IVW 0.96 (0.79-1.17) 0.687 0.687 
  Weighted Median 0.91 (0.80-1.04) 0.181 0.362 
  MR Egger 0.81 (0.58-1.14) 0.254 1.000 
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Fig 2: MR Analyses Testing Associations between Cardiometabolic Traits and 
Schizophrenia  
Forest plot presents ORs and 95% CIs for associations between cardiometabolic traits and 
schizophrenia using IVW MR analyses based on all single nucleotide polymorphisms (SNPs) 
associated with each risk factor (green) and immune-related SNPs (purple). See Table 1 and 2 
for the number of SNPs used in each analysis. HDL=High Density Lipoprotein; T2DM=Type 
2 Diabetes Mellitus; BMI=Body Mass Index; FPG=Fasting Plasma Glucose; LDL=Low-
Density Lipoprotein; HbA1C=Glycated Haemoglobin; Glucose Tol= Glucose Tolerance. 
 
Sensitivity Analysis: Adjustment for Inflammation 
MVMR analysis for inflammation-related SNPs of fasting insulin, triglycerides and HDL 
with schizophrenia showed that the univariable associations fully attenuated after controlling 
for the genetic associations of these variants with CRP. Controlling for CRP had negligible 
effect on MR estimates based on all genetic variants (Fig 3; S1-2 Results). 
 
Fig 3: Multivariable MR Analysis Testing Associations between Insulin Resistance 
Phenotypes and Schizophrenia After Controlling for Genetic Associations for CRP  
Forest plot presents ORs and 95% CIs for inverse-variance weighted regression (IVW) MR 
associations between insulin resistance phenotypes and schizophrenia using all single 
nucleotide polymorphisms (SNPs) (dark green), and after controlling for association of these 
SNPs with C-reactive protein (CRP) using multivariable MR (MVMR) (light green). The 
forest plot also presents ORs and 95% CIs for IVW MR associations between insulin 
resistance phenotypes and schizophrenia using inflammation-related SNPs (dark purple), and 
after controlling for association of these SNPs with CRP using MVMR (light purple). 
HDL=high-density lipoprotein. 
 
 
Test for Bidirectionality using Schizophrenia as Exposure 
We did not find statistically significant MR associations between schizophrenia and any 
cardiometabolic trait after correction for multiple testing (S3 Results; S1 Fig). Similarly, we 
did not find statistically significant MR associations of inflammation-related schizophrenia 
variants with cardiometabolic traits after correction for multiple testing (S4 Results; S1 Fig).  
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Test for Horizontal Pleiotropy  
We did not find statistically significant evidence for horizontal pleiotropy in any 
cardiometabolic exposure-schizophrenia analyses with the MR-Egger regression intercept 
test. However, MR-PRESSO analysis determined that horizontal pleiotropy was likely to 
have affected estimates for all ten exposures in the all-SNP analysis (all p≤0.020). Following 
outlier correction, evidence weakened for the association with leptin (MR-PRESSO IVW 
β=0.44, S.E. 0.37, p=0.445). In the inflammation-related sensitivity analyses, there was 
evidence for horizontal pleiotropy using MR-PRESSO for T2DM and LDL only.  
In the bidirectional schizophrenia-cardiometabolic factor analyses, both MR-PRESSO and 
the MR-Egger regression intercept suggested horizontal pleiotropy affecting the outcomes of 
HDL, BMI and LDL (all p<0.05). Following outlier correction, there was evidence for a 
weak protective effect of schizophrenia on BMI (β=-0.04, S.E. 0.02, p=0.014). MR-PRESSO 
additionally revealed possible horizontal pleiotropy affecting the outcomes of triglycerides, 
T2DM, and fasting insulin (all p<0.05) in the bidirectional analysis (S5-12 Results). 
 
Test for Heterogeneity of Instruments 
In the analyses based on all-SNPs, the majority of cardiometabolic traits demonstrated 
evidence of heterogeneity (S5-8 Results). There was limited evidence of heterogeneity in the 
sensitivity analyses based on inflammation-related SNPs for T2DM, BMI and HbA1C only.  
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Test for Measurement Error 
Results for the I2GX  tests for SNP-exposure associations revealed some evidence for potential 
measurement error which may have biased MR Egger analyses in the analyses with leptin, 
IGT, T2DM and schizophrenia as exposures (S13 Results). 
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Discussion 
Main Findings 
We conducted bidirectional uni- and multi-variable two-sample MR analyses using large 
publicly available genomic datasets to first examine whether there are associations that 
support a causal relationship between IR and related cardiometabolic traits and schizophrenia, 
and second, to examine whether there is evidence to support that inflammation may be a 
shared causal mechanism for IR and schizophrenia. We report that evidence in support of a 
causal association between genetically-predicted levels of triglycerides, HDL and leptin and 
schizophrenia was weak, in that the evidence of these associations did not survive correction 
for multiple testing, estimates were inconsistent across MR methods, and may have been 
affected by horizontal pleiotropy. However, we found stronger and more consistent evidence 
for an association of the IR phenotype of fasting insulin, triglycerides and HDL [11] with 
schizophrenia when we examined only genetic variants also associated with inflammation. In 
MVMR analyses adjusting for CRP, those estimates attenuated fully to the null. We found no 
evidence in bidirectional analyses in support of a causal relationship of schizophrenia with IR 
(Panels C&D in S1 Methods). Together, our results are therefore most consistent with 
inflammation as a common cause for IR and schizophrenia (Panel A in S1 Methods). 
 
Inflammation as a Common Cause for Schizophrenia and Insulin Resistance 
Three aspects of our results point toward inflammation as a common cause for IR and 
schizophrenia (Panel A in S1 Methods). First, we did not find convincing overall evidence for 
a causal relationship between IR and schizophrenia (likely ruling out Panel B in S1 Methods). 
Second, in our analyses of inflammatory-related variants for the cardiometabolic traits, we 
found strong and consistent evidence supporting that inflammation-related IR may have a 
 
 
20 
causal relationship with schizophrenia. Third, we used MVMR to evidence that after 
controlling for CRP, an archetypal general inflammatory marker, the associations between 
inflammation-related genetic variants for IR and schizophrenia completely attenuated. This 
result suggests that the observed associations for the inflammatory-related variants are at least 
in part explained by inflammation. Together, the results are consistent with the idea that 
inflammation may be a common causal mechanism for IR and schizophrenia.  
Evidence for a common-causal mechanism between IR and schizophrenia may help to 
explain why schizophrenia is associated with higher rates of IR even in early stages of illness, 
when the cumulative effects of medication and lifestyle factors are relatively small [12, 38]. 
Anti-inflammatory agents, of which several have shown promise in treating the symptoms of 
schizophrenia [39], should therefore be considered as a putative therapeutic target for 
prevention and treatment of cardiometabolic disorders in schizophrenia. 
We used CRP, an archetypal downstream inflammatory marker, as a means of gauging the 
effect of systemic inflammation in MVMR analysis, rather than hypothesizing a specific role 
for CRP in the relationship between IR and schizophrenia. Nevertheless, CRP has 
observationally shown in both cross-sectional [40] and longitudinal [41] research to be 
associated with schizophrenia, although such findings are limited by the potential of residual 
confounding and reverse causality. Interestingly however, MR findings have reported that 
genetically-predicted CRP may have a protective-effect on schizophrenia [21], with authors 
positing that a genetically-attenuated ability to produce CRP may predispose to more 
insidious and chronic infections. In our MVMR analysis, attenuation of IR-schizophrenia 
associations after controlling for CRP is consistent with inflammation being associated with 
both exposure and outcome, albeit ‘negatively’ with the latter. Further research is needed to 
explore potential mechanisms of association between CRP and schizophrenia.  
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Furthermore, many of the SNPs included in the inflammation-related analysis were 
associated with neutrophils and/or lymphocytes. A raised neutrophil to lymphocyte ratio 
(NLR) is a marker of systemic inflammation and is known to be associated with 
schizophrenia [42] and IR [43]. We were unable to find large GWAS studies conducted in 
European populations for NLR, or for other inflammatory markers which we might have used 
in MVMR analyses in place of CRP.  
Based on our findings, we are unable to completely rule out the possibility that IR may 
mediate an inflammation-schizophrenia association (Panel B in S1 Methods), since there was 
some evidence of an association between IR and schizophrenia, albeit weak and inconsistent. 
These findings are broadly similar to one previous MR study [17], which reported only weak 
evidence of an association between the homeostasis model assessment (HOMA), a measure 
of IR, on schizophrenia. Another MR study [16] reported a genetic association between 
fasting insulin and schizophrenia, although the evidence attenuated after adjustment for BMI. 
To account for BMI, we obtained summary statistics for genetic variants related to IR after 
controlling for BMI [44]. The previous MR study included an ethnically heterogeneous 
sample, increasing the potential for population stratification bias. We used genetic data from 
a more ethnically homogenous GWAS of schizophrenia [24]. Nevertheless, while our results 
in the all-SNP analysis suggested weak evidence for triglycerides and HDL, which may 
reflect an IR phenotype, the evidence did not survive correction for multiple testing and 
requires replication in future when larger GWAS samples are available. 
The implications of our findings with regard to shared causal mechanisms should not distract 
clinicians from focusing on the assessment and management of malleable lifestyle factors 
related to cardiometabolic disorders in people with schizophrenia. Factors such as poorer diet, 
reduced exercise and smoking, which are associated with schizophrenia [7, 45, 46], may 
predispose to an inflammatory state [47]. Therefore, it is possible that lifestyle factors 
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exacerbate a feedback loop between inflammation, IR and schizophrenia by increasing both 
inflammation and IR, eventually leading to T2DM and other cardiometabolic disorders such 
as obesity and CVD. In addition to the potential therapeutic potential of anti-inflammatory 
medications, malleable lifestyle factors must continue to remain crucial targets [48, 49] for 
the prevention of cardiometabolic morbidity in people with schizophrenia.  
 
Additional Findings  
We found evidence for an association between leptin and schizophrenia, though the evidence 
did not survive correction for multiple testing and may have been affected by horizontal 
pleiotropy. Leptin, primarily an adipokine known to function as a satiety factor, also 
functions as a pro-inflammatory cytokine [50] and has high structural and functional overlap 
with IL-6 [51]. Leptin levels have been reported in observational studies to be associated with 
schizophrenia [52] and correlate with IL-6 levels in people with schizophrenia [53]. Previous 
MR studies have reported evidence for associations between IL-6 and schizophrenia [21] thus 
IL-6 may represent a putative pleiotropic mechanism for our result. However, our results 
require replication when larger GWAS for leptin are available. 
We also report that after outlier correction, schizophrenia had a weak protective effect on 
BMI. This finding complements estimates from previous research [54] using linkage 
disequilibrium (LD) score regression, though we are able to advance previous findings since 
genetic correlation analyses are unable to test direction of association. This finding suggests 
that weight-gain associated with schizophrenia is unlikely to be a feature of the illness itself 
but could be attributed to iatrogenic or lifestyle effects. Moreover, the ‘lean insulin-
resistance’ phenotype may be associated with higher levels of inflammation [55], and 
warrants further research in the context of schizophrenia, particularly since in younger 
 
 
23 
patients, the ‘lean’ nature of the phenotype may mean that important cardiometabolic 
investigations may be overlooked in the clinic. 
 
Strengths and Limitations 
Strengths of this study include the use of a large set of cardiometabolic traits and large 
GWAS datasets, through which we were able to test specific biological mechanisms. We 
chose SNPs reaching genome-wide significance from large GWAS and meta-GWAS for IR 
and related cardiometabolic traits. We performed a comprehensive set of sensitivity analyses 
to check MR assumptions. Furthermore, whilst weak-instrument bias may be a factor in MR 
analysis, in two-sample MR this bias tends toward the null [56], thus would not explain the 
positive associations we describe. We corrected for multiple testing to minimise potential 
type I error. 
Our study has some limitations. We did not select SNPs in known coding regions for the 
exposures, for example the IRS-1 gene for IR [57]. We took this step on the assumption that 
many mechanisms at play may not yet be fully understood. For example, whilst the 
heritability of cardiometabolic traits such as obesity is as high as 70%, the variance currently 
explained by known genetic variants is but a small fraction of this [58]. In addition, selecting 
SNPs from many different GWAS studies featuring large sample sizes may increase the risk 
of sample-overlap between exposure and outcome variables and can bias the results in either 
direction, depending on the proportion of overlap [27]. Also, we chose a stringent p-value 
threshold to define inflammatory-related SNPs. In doing so, we may be at risk of overlooking 
some SNPs with true inflammatory associations. However, we chose this stringent p-value 
threshold since we aimed to highlight a specific biological pathway, and relaxation of p-value 
thresholds may have increased the risk of pleiotropy through other mechanisms. In the future, 
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larger and better-powered GWAS may identify more SNPs for analysis and at greater 
resolution, potentially unearthing a larger number of inflammatory-related SNPs, which 
would be helpful to confirm our findings. Additionally, the full range of gene-products from 
the genetic variants we used as proxies for the cardiometabolic traits is unknown, and so we 
are unable to comment on potential biological mechanisms of association other than 
inflammation, which may also be relevant. Finally, our analyses were based on data from 
mostly European participants, so it is unclear whether our results apply to other populations. 
Large-scale GWAS and replication of our analyses in other populations are required to 
answer this question. 
 
Conclusion 
It is well established that certain antipsychotic drugs and lifestyle factors such as smoking, 
lack of exercise and poor diet are important contributors to cardiometabolic comorbidity in 
people with schizophrenia. In addition to this, our findings suggest that inflammation may be 
a common cause for schizophrenia and cardiometabolic disorders, which may at least partly 
explain why they so commonly co-occur in clinical practice. Lifestyle modification and 
careful prescription of certain antipsychotic medications remain crucial malleable targets to 
reduce the significant impact that comorbid cardiometabolic disorders place on the quality 
and length of life in people with schizophrenia. In addition, our findings suggest that 
targeting inflammation could be an important therapeutic target for the treatment and 
prevention of cardiometabolic disorders in people with schizophrenia. Future research should 
seek to examine the biological mechanisms which underpin how inflammation can 
simultaneously increase the risk of both IR and schizophrenia. 
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S1 Methods: GWAS used for SNP Selection 
Cardiometabolic 
Exposure 
Author 
(Year)  
Consortia Ethnic Origin Sample  Settinga GWAS-
significant 
SNPs, No. 
Inflammation
-related 
SNPs, No.b 
Fasting Insulin [1] Lotta et 
al (2016) 
MAGIC European 108,557 
(101,393 
adults and 
7,164 
adolescents) 
Meta-GWAS of 
19 European 
Cohort Studies, 
participants with 
diabetes excluded 
53 5 
Triglycerides [1] Lotta et 
al (2016) 
EPIC-InterAct, 
FPLD1 
European 188,577 adults Meta-GWAS of 
45 population-
based cohort 
studies and case-
control studies. 
53 5 
HDL [1] Lotta et 
al (2016) 
EPIC-InterAct, 
FPLD1 
European 188,577 adults Meta-GWAS of 
45 population-
based cohort 
studies and case-
control studies. 
53 4 
LDL [2] Willer et 
al (2013)  
 
 
GLGC 
 
 
European, 
East Asian, 
South Asian, 
African 
173,082 adults Meta-GWAS of 
45 population-
based cohort 
studies and case-
control studies. 
79 13 
Fasting Plasma 
Glucose [3] 
Manning 
et al 
(2012) 
MAGIC European 58,074 adults Meta-GWAS of 
29 European 
population-based 
cohort studies. 
participants with 
diabetes excluded. 
22 2 
T2DM [4] Mahajan 
et al 
(2018)  
DIAGRAM European, 
East Asian, 
South Asian, 
Mexican, 
Mexican 
American 
435,387 
adults; 
(81,412 with 
T2DM and 
370,832 
controls) 
Meta-GWAS of 
two large 
prospective 
European cohort 
studies 
152 7 
BMI [5] Locke et 
al (2015) 
GIANT European, 
African, Asian 
339,224 adults Meta-GWAS of 
125 European 
97 6 
 2 
cohort studies, 
adjusted for age 
HbA1C [6] Wheeler 
et al 
(2017)  
MAGIC European, 
African 
American, 
East Asian, 
South Asian 
 
159,940 adults Meta-GWAS of 
82 population-
based cohort 
studies. 
Participants with 
diabetes excluded. 
60 7 
Glucose 
Tolerance [7] 
Saxena et 
al (2010) 
MAGIC European 
 
15,234 adults Meta-GWAS of 9 
population-based 
cohort studies. 
Participants with 
diabetes excluded. 
7 0 
Leptin [8] Kilpelain
en et al 
(2016) 
- European 
 
82,315 adults Meta-GWAS of 
32 population-
based cohort 
studies adjusted 
for age and sex. 
5 0 
SNP=Single Nucleotide Polymorphism; GWAS=Genome-Wide Association Study; HDL=High-Density 
Lipoprotein; LDL=Low-Density Lipoprotein; T2DM=Type 2 Diabetes Mellitus; BMI=Body Mass Index; 
HbA1C=Glycated Haemoglobin; MAGIC=Meta-Analysis of Glucose and Insulin Related traits Consortium; 
GLGC=Global Lipids Genetics Consortium; DIAGRAM=Diabetes Genetics Replication and Meta-Analysis; 
GIANT=Genetic Investigation of Anthropometric Traits 
aSee original GWAS publication for detailed demographic and setting information for studies included in 
meta-GWAS. 
bNumber of SNPs with pleiotropy for inflammation at genome-wide significance 
 
S2 Methods: SNPs used as instruments for fasting insulin, triglycerides and high-density lipoprotein 
rs4846565 
rs10195252 
rs2943645 
rs308971 
rs3822072 
rs6822892 
rs4865796 
rs459193 
rs2745353 
rs731839 
rs683135 
rs2249105 
rs492400 
rs3864041 
rs295449 
rs11130329 
rs9881942 
rs645040 
rs2699429 
rs4976033 
rs6887914 
rs1045241 
rs9492443 
rs3861397 
rs17169104 
rs972283 
rs2126259 
rs1011685 
rs4738141 
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S3 Methods: SNPs used as instruments for fasting plasma glucose 
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S4 Methods: SNPs used as instruments for type 2 diabetes mellitus 
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S5 Methods: SNPs used as instruments for body mass index 
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S6 Methods: SNPs used as instruments for glucose tolerance 
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S7 Methods: SNPs used as instruments for low density lipoprotein 
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S8 Methods: SNPs used as instruments for glycated haemoglobin 
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S9 Methods: SNPs used as instruments for leptin 
 
 
 
 
 
 
 
 
 
S10 Methods: Directed Acyclic Graphs Outlining Potential Mechanisms of Association between 
Inflammation, Insulin Resistance and Schizophrenia 
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A=Represents mechanism whereby inflammation is a common cause for insulin resistance and 
schizophrenia; B=Represents mechanism whereby insulin resistance mediates an association between 
inflammation and schizophrenia; C=Represents mechanism whereby schizophrenia is a common cause for 
insulin resistance and inflammation; D=Represents mechanism whereby insulin resistance mediates an 
association between schizophrenia and inflammation. 
 
 
 
S11 Methods: MR Analysis Methods 
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Insulin Resistance 
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Inflammation 
Insulin Resistance 
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Inflammation 
Insulin Resistance 
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Insulin Resistance 
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Inverse Weighted Variance (IVW) Method 
IVW consists of a weighted linear regression of SNP-exposure SNP-outcome effect estimates. The IVW 
estimate is the inverse variance weighted mean of ratio estimates from 2 or more instruments [9], and 
assumes that all SNPs are valid instruments or that the sum of directional bias is zero. Since the intercept is 
an estimate of average pleiotropic effects across IVs, in an IVW approach the intercept is fixed to 0.  
 
Weighted Median 
The weighted median is the median of the weighted empirical distribution function of individual SNP ratio 
estimates. This method provides a consistent effect estimate if more than 50% of the information comes from 
valid SNPs [10].  
 
MR Egger 
MR-Egger regression consists of a weighted linear regression similar to IVW, with the assumption that 
horizontal pleiotropic effects and SNP-exposure associations are uncorrelated (i.e. the InSIDE assumption is 
not violated) [11], therefore the intercept is not fixed. MR Egger regression provides a valid effect estimate 
even if all SNPs are invalid instruments but assumes that uncertainty in the SNP-exposure association 
estimates is negligible (the ‘NOME’ assumption [12]).  
 
Mendelian Randomization Pleiotropy Residual Sum and Outlier (MR-PRESSO) Test 
MR-PRESSO [13] relies on a regression framework where the variants’ effects on the outcome are regressed 
on the same variants’ effects on exposure, with the slope of the regression line providing an estimate of the 
causal effect of the exposure on the outcome. The MR-PRESSO global test evaluates overall horizontal 
pleiotropy amongst all IVs in a single MR test by comparing the observed distance of all the variants to the 
regression line (residual sum of squares) to the expected distance under the null hypothesis of no horizontal 
pleiotropy. The MR-PRESSO outlier test evaluates the presence of specific horizontal pleiotropic outlier 
variants by using the observed and expected distributions of the tested variant. Finally, the MR-PRESSO 
distortion test evaluates the significance of the distortion between the causal estimate before and after 
removal of the horizontal pleiotropic outlier variants (detected from the outlier test of MR-PRESSO). 
 
 
S12 Methods: Inflammation-related SNPs for fasting insulin, triglycerides and high-density 
lipoprotein 
 7 
SNP Inflammation-Related Pleiotropy Effect Allele 
rs11577194 Macrophage Colony Stimulating Factor T 
rs295449 Lymphocyte Count, White Cell Count A 
rs645040 CRP T 
rs9492443 Lymphocyte Count, Neutrophil Count C 
rs2126259 CRP, Neutrophil Count, Granulocyte Count, Basophil Count, Myeloid 
White Cell Count 
T 
CRP=C-reactive protein 
 
S13 Methods: Inflammation-related SNPs for low density lipoprotein 
SNP Inflammation-Related Pleiotropy Effect Allele 
rs1169288 CRP C 
rs17404153 C-C motif chemokine 21, Neutrophil% G 
rs174583 Neutrophil%, Basophils, WCC, Eosinophils C 
rs1800961 CRP, Neutrophil%, Basophils C 
rs2642438 Granulocyte Count, Monocyte Count G 
rs2886232 C-C motif chemokine 22, Neutrophil%,  T 
rs2954029 Neutrophil%, Eosinophils A 
rs3184504 Eosinophils, Basophils, Lymphocyte%, WCC, Neutrophil%, IL-2b  C 
rs4970712 Monocyte Count, Granulocyte Count, Lymphocyte% C 
rs579459 IL-3a, Neutrophil%, Eosinophils, WCC, IL-6 C 
rs646776 CRP, C1q complement T 
rs9875338 Monocyte Count, Neutrophil% G 
rs9987289 CRP, Neutrophil%, Basophils  G 
CRP=C-reactive protein; WCC=White Cell Count; IL-=interleukin-. 
 
S14 Methods: Inflammation-related SNPs for fasting plasma glucose 
SNP Inflammation-Related Pleiotropy Effect Allele 
rs780093 Monocyte Count, Basophils, Neutrophil% T 
rs983309 Neutrophil%, Granulocytes T 
 
 
 
 
 
 
 
 
S15 Methods: Inflammation-related SNPs for glycated haemoglobin 
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SNP Inflammation-Related Pleiotropy Effect Allele 
rs1260326 
CRP, Basophil Count, Neutrophil Count, 
Lymphocyte Count C 
rs2276853 
Lymphocyte Count, Neutrophil Count, 
Granulocyte Count A 
rs2073721 Neutrophil Count, Granulocyte Count G 
rs1169288 CRP C 
rs1060105 Lymphocyte Count, Neutrophil Count C 
rs9891146 
Neutrophil Count, Eosinophil Count, 
Lymphocyte Count T 
rs1800961 
CRP, Neutrophil Count, Granulocyte Count, 
Basophil Count T 
CRP=C-reactive protein 
 
S16 Methods: Inflammation-related SNPs for type 2 diabetes mellitus 
SNP Inflammation-Related Pleiotropy Effect Allele 
rs1260326 
CRP, Basophil Count, Neutrophil Count, 
Lymphocyte Count C 
rs2276853 
Lymphocyte Count, Neutrophil Count, 
Granulocyte Count A 
rs2073721 Neutrophil Count, Monocyte %, Granulocyte % G 
rs1169288 CRP C 
rs1060105 Neutrophil Count, Lymphocyte Count C 
rs9891146 
Neutrophil Count, Eosinophil Count, Granulocyte 
Count T 
rs1800961 
 
CRP, Neutrophil Count, Granulocyte Count, 
Basophil Count, Myeloid Count T 
CRP=C-reactive protein 
 
S17 Methods: Inflammation-related SNPs for body mass index 
SNP Inflammation-Related Pleiotropy Effect Allele 
rs16851483 Monocyte count G 
rs891389 Neurotrophil%, Eosinophils, Basophils C 
rs1558902 CRP  A 
rs1808579 Neurotrophil%, Eosinophils T 
rs571312 CRP A 
rs16851483 Monocyte count G 
CRP=C-reactive protein 
 
 
 
 
 
S18 Methods: Inflammation-related SNPs for schizophrenia 
 9 
SNP Inflammation-Related Pleiotropy 
Effect 
Allele 
rs2851447 Lymphocyte%, Neutrophil% G 
rs3130820 Lymphocyte Count, Basophil Count, Monocyte count T 
rs4925114 Lymphocyte Count T 
rs12416331 Monocyte Count A 
rs7216638 White cell count, Basophil count T 
 
 
 
S19 Methods: SNPs used for CRP in MVMR Analysis 
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S1 Results: Multivariable MR (MVMR) Resultsa for IR-Phenotype Exposures (All-SNP analysis) with 
Addition of CRP as Exposure 
 
 
 
 
 
 
 
CRP=C-reactive protein; HDL=high-density lipoprotein; SNPs=single nucleotide polymorphisms 
aResults for IVW MVMR analysis 
bWe did not perform univariable MR analysis for CRP since this was not a goal of the study. Univariable 
MR has been conducted and replicated for CRP and estimates are published elsewhere [14, 15] 
 
 
 
S2 Results: Multivariable MR (MVMR) Resultsa for IR-Phenotype Exposures (Inflammation-related-
SNP analysis) with Addition of CRP as Exposure 
 
 
 
 
 
 
 
CRP=C-reactive protein; HDL=high-density lipoprotein; SNPs=single nucleotide polymorphisms 
aResults for IVW MVMR analysis 
bWe did not perform univariable MR analysis for CRP since this was not a goal of the study. Univariable 
MR has been conducted and replicated for CRP and estimates are published elsewhere [14, 15] 
 
 
 
 
 
 
 
S3 Results: MR Analyses using all SNPs for Schizophrenia and Cardiometabolic Outcomes 
Risk Factor no. SNPs Odds Ratio (95% C.I.) P-value 
Fasting Insulin 46 0.93 (0.71-1.21) 0.595 
CRP 3 0.76 (0.48-1.20)b 0.233 
Triglycerides 46 0.89 (0.73-1.10) 0.296 
CRP 3 0.73 (0.48-1.14)b 0.168 
HDL 46 1.12 (0.93-1.36) 0.209 
CRP 3 0.73 (0.46-1.14)b 0.167 
Risk Factor no. SNPs Odds Ratio (95% C.I.) P-value 
Fasting Insulin 5 0.95 (0.55-1.62) 0.645 
CRP 3 0.77 (0.33-3.49)b 0.727 
Triglycerides 5 0.79 (0.58-1.21) 0.203 
CRP 3 0.89 (0.48-1.66)b 0.717 
HDL 4 1.48 (0.66-3.33) 0.340 
CRP 3 1.86 (0.79-4.36)b 0.155 
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HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein; SNPs=single 
nucleotide polymorphisms; IVW=inverse variance weighted regression; β=beta coefficient; S.E=standard 
error. aAdjusted using the Holm-Bonferroni method for multiple testing. 
S4 Results: The Association between Inflammation-Related Schizophrenia SNPs and Cardiometabolic 
Outcomes  
Outcome SNPs, 
No. 
Method β (S.E) P-value Corrected p-
valuea 
Fasting Insulin 101 IVW 0.01 (0.02) 0.496 1.000 
  Weighted Median 0.02 (0.02) 0.268 1.000 
  MR Egger -0.05 (0.08) 0.542 1.000 
Triglycerides 101 IVW 0.00 (0.02) 0.970 1.000 
  Weighted Median 0.00 (0.03) 0.987 1.000 
  MR Egger 0.05 (0.11) 0.642 1.000 
HDL 101 IVW -0.02 (0.03) 0.521 1.000 
  Weighted Median -0.01 (0.03) 0.901 1.000 
  MR Egger -0.04 (0.05) 0.051 0.510 
Fasting Plasma Glucose 105 IVW 0.01 (0.01) 0.339 1.000 
  Weighted Median 0.01 (0.01) 0.454 1.000 
  MR Egger 0.00 (0.06) 0.994 1.000 
Type 2 Diabetes Mellitus 109 IVW -0.01 (0.06) 0.845 1.000 
  Weighted Median 0.00 (0.08) 1.000 1.000 
  MR Egger 0.14 (0.30) 0.645 1.000 
Body Mass Index 101 IVW -0.03 (0.02) 0.220 1.000 
  Weighted Median -0.03 (0.02) 0.146 1.000 
  MR Egger 0.18 (0.10) 0.081 0.729 
HbA1C 104 IVW 0.01 (0.01) 0.911 1.000 
  Weighted Median 0.01 (0.02) 0.730 1.000 
  MR Egger 0.01 (0.07) 0.948 1.000 
Glucose Tolerance 101 IVW 0.08 (0.07) 0.278 1.000 
  Weighted Median 0.12 (0.10) 0.233 1.000 
  MR Egger 0.24 (0.35) 0.496 1.000 
LDL 101 IVW -0.06 (0.03) 0.079 0.790 
  Weighted Median -0.06 (0.05) 0.080 0.800 
  MR Egger -0.22 (0.14) 0.113 0.904 
Leptin 101 IVW 0.02 (0.02) 0.239 1.000 
  Weighted Median 0.01 (0.03) 0.677 1.000 
  MR Egger -0.02 (0.09) 0.810 1.000 
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HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein; SNPs=single 
nucleotide polymorphisms; IVW=inverse variance weighted regression; β=beta coefficient; S.E=standard 
error. aAdjusted using the Holm-Bonferroni method for multiple testing. 
 
S5 Results: Cochran’s Q Tests for Heterogeneity and MR Egger Intercept Tests for Horizontal 
Pleiotropy for the Association between all Cardiometabolic SNPs and Schizophrenia 
Outcome No. 
immune 
SNPs 
Method β (S.E) P-value Corrected 
P-valuea 
 
Fasting Insulin 3 IVW 0.04 (0.05) 0.409 1.000 
  Weighted Median 0.03 (0.06) 0.666 1.000 
  MR Egger 0.00 (0.09) 0.976 1.000 
Triglycerides 3 IVW 0.20 (0.09) 0.034 0.340 
  Weighted Median 0.20 (0.08) 0.009 0.090 
  MR Egger 0.28 (0.30) 0.306 1.000 
HDL 1 Wald Ratio -0.26 (0.21) 0.202 1.000 
LDL 3 IVW 0.11 (0.07) 0.953 1.000 
  Weighted Median 0.06 (0.07) 0.341 1.000 
  MR Egger -0.01 (0.10) 0.895 1.000 
Body Mass Index 4 IVW -0.02 (0.09) 0.750 1.000 
  Weighted Median 0.00 (0.05) 0.832 1.000 
  MR Egger 0.05 (0.02) 0.705 1.000 
Type 2 Diabetes Mellitus 3 IVW -0.18 (0.34) 0.598 1.000 
  Weighted Median 0.10 (0.30) 0.729 1.000 
  MR Egger 0.24 (0.80) 0.789 1.000 
Fasting Plasma Glucose 4 IVW -0.02 (0.07) 0.780 1.000 
  Weighted Median -0.05 (0.04) 0.317 1.000 
  MR Egger -0.16 (0.10) 0.258 1.000 
HbA1C 3 IVW -0.07 (0.07) 0.269 1.000 
  Weighted Median 0.06 (0.05) 0.137 1.000 
  MR Egger -0.18 (0.12) 0.292 1.000 
Glucose Tolerance 4 IVW 0.12 (0.26) 0.648 1.000 
  Weighted Median 0.10 (0.31) 0.732 1.000 
  MR Egger -0.09 (0.49) 0.872 1.000 
Leptin 4 IVW -0.03 (0.07) 0.646 1.000 
  Weighted Median -0.04 (0.08) 0.619 1.000 
  MR Egger -0.10 (0.12) 0.526 1.000 
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 IVW MR Egger 
 
Cardiometabolic Risk Factor Cochran’s 
Q (df) 
p-
value 
Cochran’s 
Q (df) 
p-value MR Egger 
Intercept 
(SE) 
Intercept 
p-value 
Fasting Insulin 127.25 (52) <0.001 119.15 (51) <0.001 -0.01 (0.01) 0.080 
Triglycerides 120.87 (52) <0.001 132.10 (51) <0.001 -0.01 (0.01) 0.080 
HDL 132.07 (52) <0.001 119.62 (51) <0.001 0.01 (0.01) 0.090 
Fasting Plasma Glucose 50.11 (21) <0.001 49.90 (20) <0.001 <0.01 (0.01) 0.773 
Type 2 Diabetes Mellitus 196.81 (39) <0.001 196.72 (38) <0.001 <0.01 (0.01) 0.850 
Body Mass Index 522.85 (138) <0.001 520.66 (137) <0.001 <0.01 (0.00) 0.448 
HbA1C 8.43 (59) 0.587 3.88 (58) 0.920 -0.02 (0.00) 0.061 
Glucose Tolerance 14.47 (6) 0.024 7.47 (5) 0.188 -0.06 (0.03) 0.083 
Leptin 0.39 (1) 0.533 6.76 (2) 0.034 -0.16 (0.06) 0.240 
LDL 141.44 (75) <0.001 141.39 (74) <0.001 <0.01 (0.00) 0.873 
IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; HDL=high-density 
lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
 
 
 
 
 
 
 
S6 Results: Cochran’s Q Tests for Heterogeneity and MR Egger Intercept Tests for Horizontal 
Pleiotropy for the Association between Inflammation-Related Cardiometabolic SNPs and 
Schizophrenia 
 IVW MR Egger 
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Cardiometabolic Risk 
Factor 
Cochran’s 
Q (df) 
p-value Cochran’s Q 
(df) 
p-
value 
Regression 
Intercept (SE) 
Direction 
p-value 
Fasting Insulin 11.42 (4) 0.022 11.12 (3) 0.011 -0.01 (0.02) 0.796 
Triglycerides 9.65 (4) 0.013 12.32 (3) 0.009 0.04 (0.02) 0.129 
HDL 14.32 (4) 0.008 9.70 (3) 0.032 -0.03 (0.02) 0.215 
Type 2 Diabetes Mellitus 1.30 (6) 0.971 1.27 (5) 0.938 0.00 (0.02) 0.151 
Fasting Plasma Glucose 7.08 (1) 0.008 * * * * 
HbA1C 8.08 (7) 0.325 7.75 (6) 0.258 0.00 (0.01) 0.628 
Body Mass Index 5.44 (3) 0.142 0.29 (2) 0.864 0.03 (0.01) 0.151 
LDL 37.29 (11) <0.001 32.65 (10) <0.001 0.01 (0.01) 0.261 
IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; HDL=high-density 
lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
*insufficient n SNPs 
 
 
 
 
 
 
 
 
 
 
 
 
S7 Results: Cochran’s Q Tests for Heterogeneity and MR Egger Intercept Tests for Horizontal 
Pleiotropy for the Association between Schizophrenia SNPs and Cardiometabolic Outcomes 
 IVW MR Egger 
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Cardiometabolic Outcome Cochran’s 
Q (df) 
p-
value 
Cochran’s 
Q (df) 
p-
value 
Regression 
Intercept 
(SE) 
Direction p-
value 
Fasting Insulin 129.93 (1000 0.024 128.96 (99) 0.023 0.00 (0.00) 0.442 
Triglycerides 205.86 (100) <0.001 205.37 (99) <0.001 0.00 (0.00) 0.628 
HDL 373.38 (100) <0.001 353.54 (99) <0.001 0.01 (0.00) 0.020 
Fasting Plasma Glucose 125.03 (104) 0.078 124.98 
(103) 
0.069 0.00 (0.00) 0.843 
Type 2 Diabetes Mellitus 139.83 (108) 0.021 139.50 
(107) 
0.019 0.00 (0.01) 0.612 
Body Mass Index 264.27 (100) <0.001 264.80 (99) <0.001 -0.01 (0.00) 0.041 
HbA1C 131.35 (103) 0.031 131.34 
(102) 
0.027 0.00 (0.00) 0.966 
Glucose Tolerance 110.78 (100) 0.217 110.54 (99) 0.201 -0.01 (0.01) 0.642 
Leptin 6.76 (2) 0.034 0.388 (1) 0.533 -0.16 (0.06) 0.240 
LDL 183.06 (100) <0.001 175.38 (99) <0.001 0.01 (0.00) 0.040 
IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; HDL=high-density 
lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
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S8 Results: Cochran’s Q Tests for Heterogeneity and MR Egger Intercept Tests for Horizontal 
Pleiotropy for the Association between Inflammation-Related Schizophrenia SNPs and 
Cardiometabolic Outcomes 
IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; HDL=high-density 
lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
*insufficient n SNPs 
 
 
 
 
 
 
 
 IVW MR Egger 
 
Cardiometabolic 
Outcome 
Cochran’s Q 
(df) 
p-value Cochran’s Q 
(df) 
p-value Regression 
Intercept 
(SE) 
Direction 
p-value 
Fasting Insulin 6.83 (5) 0.233 6.50 (4) 0.165 0.00 (0.00) 0.676 
Triglycerides 73.73 (5) <0.001 56.79 (4) <0.001 -0.02 (0.02) 0.336 
HDL 4.00 (1) 0.050 * * * * 
Type 2 Diabetes Mellitus 13.30 (5) 0.021 11.10 (4) 0.026 0.02 (0.03) 0.421 
Fasting Plasma Glucose 6.91 (3) 0.075 2.97 (2) 0.226 0.01 (0.01) 0.245 
Body Mass Index 36.18 (5) <0.001 25.96 (4) <0.001 -0.01 (0.01) 0.278 
LDL 4.36 (2) 0.113 0.16 (1) 0.687 0.01 (0.00) 0.289 
HbA1C 6.24 (3) 0.100 4.21 (2) 0.121 0.00 (0.00) 0.430 
Glucose Tolerance 0.80 (2) 0.671 0.787 (1) 0.375 0.00 (0.03) 0.941 
Leptin 0.42 (2) 0.812 0.351 (1) 0.554 0.00 (0.00) 0.841 
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S9 Results: MR-PRESSO Tests of Cardiometabolic All-SNP Analysis to Examine For and Correct 
Horizontal Pleiotropy 
MR PRESSO= Mendelian Randomization Pleiotropy Residual Sum and Outlier; β=beta coefficient; 
S.E=standard error. IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; 
HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
*no evidence of horizontal pleiotropy 
 
 
 
 
 
 
 
 
 
 
 
Risk Factor MR-PRESSO Global 
Test 
Outlier-Corrected 
IVW 
Distortion Test 
RSS p-value β (SE) p-value Coefficient p-
value 
Fasting Insulin 151.23 <0.001 -0.04 (0.15) 0.554 76.54 0.451 
Triglycerides 155.89 <0.001 -0.08 (0.10) 0.210 69.49 0.388 
HDL 148.35 <0.001 0.01 (0.08) 0.908 429.50 0.091 
Fasting Plasma Glucose 53.78 <0.001 0.03 (0.05) 0.594 120.88 0.300 
Type 2 Diabetes Mellitus 47.76 <0.001 0.11 (0.13) 0.437 162.05 0.219 
Body Mass Index 330.12 <0.001 0.01 (0.07) 0.869 326.33 0.147 
HbA1C 69.85 <0.001 0.06 (0.11) 0.604 -82.14 0.821 
Glucose Tolerance 20.77 0.020 * * * * 
LDL 148.15 <0.001 -0.01 (0.03) 0.581 46.44 0.840 
Leptin 40.37 <0.001 0.44 (0.37) 0.445 -7.44 <0.001 
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S10 Results: MR-PRESSO Tests of Inflammation-Related Cardiometabolic SNPs to Examine For and 
Correct Horizontal Pleiotropy 
MR PRESSO= Mendelian Randomization Pleiotropy Residual Sum and Outlier; β=beta coefficient; 
S.E=standard error. IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; 
HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
*no evidence of horizontal pleiotropy; †no identified outliers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk Factor MR-PRESSO Global 
Test 
Outlier-Corrected 
IVW 
Distortion Test 
RSS p-value β (SE) p-value Coefficient p-value 
Fasting Insulin 14.88 0.081 * * * * 
Triglycerides 16.50 0.103 * * * * 
HDL 20.23 0.144 * * * * 
Type 2 Diabetes Mellitus 47.76 0.001 0.11 (0.13) 0.436 -162.05 0.210 
Body Mass Index 23.75 0.026 † † † † 
HbA1C 10.24 0.447 * * * * 
LDL 50.16 <0.001 0.00 (0.07) 0.968 -261.84 0.015 
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S11 Results: MR-PRESSO Tests of Schizophrenia All-SNP Analysis to Examine For and Correct 
Horizontal Pleiotropy 
MR PRESSO= Mendelian Randomization Pleiotropy Residual Sum and Outlier; β=beta coefficient; 
S.E=standard error. IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; 
HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
*no evidence of horizontal pleiotropy; †no identified outliers 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome MR-PRESSO Global 
Test 
Outlier-Corrected 
IVW 
Distortion Test 
RSS p-value β (SE) p-value Coefficient p-
value 
Fasting Insulin 161.53 0.020 † † † † 
Triglycerides 249.82 <0.001 0.00 (0.02) 0.210 590.84 0.064 
HDL 434.93 <0.001 -0.01 (-0.02) 0.567 117.13 0.251 
Fasting Plasma Glucose 155.12 0.067 * * * * 
Type 2 Diabetes Mellitus 174.18 0.012 † † † † 
Body Mass Index 372.10 <0.001 -0.04 (0.02) 0.014 1.89 0.966 
HbA1C 149.23 0.107 * * * * 
Glucose Tolerance 137.63 0.235 * * * * 
LDL 216.08 <0.001 0.00 (0.02) 0.866 -501.07 0.100 
Leptin 113.87 0.772 * * * * 
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S12 Results: MR-PRESSO Tests of Inflammation-Related Schizophrenia SNP Analysis to Examine 
For and Correct Horizontal Pleiotropy 
MR PRESSO= Mendelian Randomization Pleiotropy Residual Sum and Outlier; β=beta coefficient; 
S.E=standard error. IVW=inverse variance weighted regression; df=degrees of freedom; SE=standard error; 
HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
*no evidence of horizontal pleiotropy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome MR-PRESSO Global Test Outlier-Corrected IVW Distortion Test 
RSS p-value β (SE) p-value Coefficient p-value 
Fasting Insulin 1.08 0.883 * * * * 
Triglycerides 23.51  0.058 * * * * 
HDL 9.56 0.276 * * * * 
Fasting Plasma Glucose 15.34 0.095 * * * * 
Type 2 Diabetes Mellitus 18.41 0.048 0.22 (0.09) 0.144 -182.77 <0.001 
Body Mass Index 15.11 0.128 * * * * 
HbA1C 10.81 0.182 * * * * 
Glucose Tolerance 2.54 0.729 * * * * 
LDL 14.13 0.165 * * * * 
Leptin 3.29 0.647 * * * * 
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S13 Results: I2GX Statistics to Examine for Potential Violation of NOME Assumption for MR Egger 
Analyses 
 I2GX of SNP-Exposure Associations 
Exposure All-SNP Analyses Inflammation-
Related SNP 
Analyses 
Fasting Insulin 0.86 0.94 
Triglycerides 0.98 0.96 
HDL 0.98 0.99 
Fasting Plasma Glucose 0.95 0.99 
Type 2 Diabetes Mellitus 0.84 0.65 
Body Mass Index 0.93 0.99 
HbA1C 0.93 0.93 
Glucose Tolerance 0.51 * 
Leptin 0.00 * 
LDL 0.99 0.98 
Schizophrenia 0.00 0.83 
HDL=high-density lipoprotein; HbA1C=glycated haemoglobin; LDL=low-density lipoprotein. 
*insufficient n SNPs 
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S1 Checklist: STROBE-MR: Guidelines for strengthening the reporting of Mendelian randomization 
studies [16] 
1. TITLE and ABSTRACT  
Indicate Mendelian randomization as the study’s design in the title and/or the abstract.  
Title; Abstract – Methods & Findings. 
 
INTRODUCTION 2. Background     
Explain the scientific background and rationale for the reported study. Is causality between 
exposure and outcome plausible? Justify why MR is a helpful method to address the study 
question.  
Introduction – Paragraphs 1-2. 
 
3. Objectives    
State specific objectives clearly, including pre-specified causal hypotheses (if any).    
Introduction – Paragraph 4. 
  
METHODS  
4. Study design and data sources  
Present key elements of study design early in the paper. Consider including a table listing 
sources of data for all phases of the study.  
Methods – Paragraph 1; S1 Methods. 
 
5. Assumptions  
Explicitly state assumptions for the main analysis (e.g. relevance, exclusion, independence, 
homogeneity) as well assumptions for any additional or sensitivity analysis.   
Methods – Statistical Analysis – Paragraph 1-2; S10 Methods. 
  
6. Statistical methods: main analysis   
Describe statistical methods and statistics used.  
a) Describe how quantitative variables were handled in the analyses (i.e., scale, units, 
model).   
Methods – Statistical Analysis – Paragraph 1. 
b) Describe the process for identifying genetic variants and weights to be included in the 
analyses (i.e, independence and model) 
Methods – Statistical Analysis – Paragraph 1. 
c) Describe the MR estimator, e.g. two-stage least squares, Wald ratio, and related 
statistics. Detail the included covariates and, in case of two-sample MR, whether the 
same covariate set was used for adjustment in the two samples.  
Methods – Statistical Analysis – Paragraph 1; S10 Methods. 
d) If applicable, say how multiple testing was dealt with.  
Methods – Correction for Multiple Testing – Paragraph 1. 
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7. Assessment of assumptions   
Describe any methods used to assess the assumptions or justify their validity.  
Methods – Statistical Analysis – Paragraph 2. 
  
8. Sensitivity analyses  
Describe any sensitivity analyses or additional analyses performed.  
Methods – Statistical Analysis – Paragraph 2; Methods – Analysis using Inflammation-Related 
SNPs – Paragraphs 1-2; Methods – Sensitivity Analysis – Adjustment for Inflammation – 
Paragraph 1. 
  
9. Software and pre-registration  
a) Name statistical software and package(s), including version and settings used.     
Methods – Statistical Analysis – Paragraph 1. 
b) State whether the study protocol and details were pre-registered (as well as when and 
where).  
Methods – Statistical Analysis – Paragraph 1. 
  
RESULTS 10. Descriptive data  
a) For two-sample Mendelian randomization:   
Provide information on extent of sample overlap between the exposure and 
outcome data sources.  
Methods – Selection of Genetic Variants Related to Cardiometabolic Traits and 
Schizophrenia – Paragraph 1. 
 
 
11. Main results  
a) Report the associations between genetic variant and exposure, and between genetic 
variant and outcome, preferably on an interpretable scale (e.g. comparing 25th and 75th 
percentile of allele count or genetic risk score, if individual-level data available).   
Figure 1, Figure 2, Figure S1. 
b) Report causal effect estimate between exposure and outcome, and the measures of 
uncertainty from the MR analysis. Use an intuitive scale, such as odds ratio, or relative 
risk, per standard deviation difference.  
Results Table 1; Results Table 2; S1 Results; S2 Results; S3 Results; S4 Results.  
c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time-period.  
N/A. 
d) Consider any plots to visualize results (e.g. forest plot, scatterplot of associations 
between genetic variants and outcome versus between genetic variants and exposure).   
Figure 1, Figure 2, Figure S1. 
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12. Assessment of assumptions  
a) Assess the validity of the assumptions.   
Results – Test for Horizontal Pleiotropy – Paragraphs 1&2; Results – Test for 
Heterogeneity of Instruments – Paragraph 1; Results – Test for Measurement Error – 
Paragraph 1. 
b) Report any additional statistics (e.g., assessments of heterogeneity, such as I2, Q 
statistic).   
S5-S13 Results. 
  
13. Sensitivity and additional analyses  
a) Use sensitivity analyses to assess the robustness of the main results to violations of the 
assumptions.  
S5-S13 Results. 
b) Report results from other sensitivity analyses (e.g., replication study with different 
dataset, analyses of subgroups, validation of instrument(s), simulations, etc.) 
Results – MR Analyses using Inflammation-related Genetic Variants for IR and Other 
Cardiometabolic Traits – Paragraph 1; Results – Sensitivity Analysis: Adjustment for 
Inflammation – Paragraph 1; Table 2; S1-2 Results. 
c) Report any assessment of direction of causality (e.g., bidirectional MR).  
Results – Test for Bidirectionality using Schizophrenia as Exposure – Paragraph 1. 
 
 
DISCUSSION 14. Key results    
Summarize key results with reference to study objectives.  
Discussion – Paragraph 1. 
  
15. Limitations   
Discuss limitations of the study, taking into account the validity of the MR assumptions, other 
sources of potential bias, and imprecision. Discuss both direction and magnitude of any 
potential bias, and any efforts to address them. 
Discussion – Strengths and Limitations – Paragraph 2. 
 
16. Interpretation  
a) Give a cautious overall interpretation of results considering objectives and limitations. 
Compare with results from other relevant studies.  
Discussion – Conclusion – Paragraph 1. 
b) Discuss underlying biological mechanisms that could be modelled by using the genetic 
variants to assess the relationship between the exposure and the outcome.   
Discussion – Inflammation as a Common Cause for Schizophrenia and Insulin 
Resistance – Paragraphs 1-6. 
c) Discuss whether the results have clinical or policy relevance, and whether interventions 
could have the same size effect.    
Discussion – Conclusion – Paragraph 1. 
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17. Generalizability     
Discuss the generalizability of the study results (a) to other populations (i.e. external validity), 
(b) across other exposure periods/timings, and (c) across other levels of exposure.   
Discussion – Paragraphs 1-11. 
 
OTHER INFORMATION 18. Funding     
Give the source of funding and the role of the funders for the present study and, if applicable, 
for the original study or studies on which the present article is based.  
Funding Statement 
 
19. Data and data sharing     
Present data used to perform all analyses or report where and how the data can be accessed. 
State whether statistical code is publicly accessible and if so, where.  
Data Availability Statement 
 
20. Conflicts of Interest     
All authors should declare all potential conflicts of interest.    
 Competing Interest Statement 
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S2 Checklist: STROBE Statement 
 
 Item 
No Recommendation 
Where Located 
Title and abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract 
Title 
(b) Provide in the abstract an 
informative and balanced summary of 
what was done and what was found 
Abstract – Methods & Findings 
Introduction 
Background/rationale 2 Explain the scientific background and 
rationale for the investigation being 
reported 
Introduction Paragraphs 1-3 
Objectives 3 State specific objectives, including any 
prespecified hypotheses 
Introduction Paragraph 4 
Methods 
Study design 4 Present key elements of study design 
early in the paper 
Introduction Paragraph 4; Methods – 
Statistical Analysis Paragraph 1; S10 
Methods 
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, and 
data collection 
Methods – Selection of Genetic Variants 
Related to Cardiometabolic Traits and 
Schizophrenia – Paragraph 1; S1-10 
Methods 
Participants 6 (a) Cohort study—Give the eligibility 
criteria, and the sources and methods of 
selection of participants. Describe 
methods of follow-up 
Case-control study—Give the 
eligibility criteria, and the sources and 
methods of case ascertainment and 
control selection. Give the rationale for 
the choice of cases and controls 
Cross-sectional study—Give the 
eligibility criteria, and the sources and 
methods of selection of participants 
Methods – Selection of Genetic Variants 
Related to Cardiometabolic Traits and 
Schizophrenia – Paragraph 1; S1 
Methods 
(b) Cohort study—For matched studies, 
give matching criteria and number of 
exposed and unexposed 
Case-control study—For matched 
studies, give matching criteria and the 
number of controls per case 
Methods – Selection of Genetic Variants 
Related to Cardiometabolic Traits and 
Schizophrenia – Paragraph 1; S1 
Methods 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and 
effect modifiers. Give diagnostic 
criteria, if applicable 
Methods – Selection of Genetic Variants 
Related to Cardiometabolic Traits and 
Schizophrenia – Paragraph 1; S1 
Methods 
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Data sources/ 
measurement 
8*  For each variable of interest, give 
sources of data and details of methods 
of assessment (measurement). Describe 
comparability of assessment methods if 
there is more than one group 
Methods – Selection of Genetic Variants 
Related to Cardiometabolic Traits and 
Schizophrenia – Paragraph 1; S1-S9 
Methods; Methods – Statistical Analysis 
– Parahraphs 1-2 
Bias 9 Describe any efforts to address 
potential sources of bias 
Methods – Statistical Analysis – 
Paragraph 2 
Study size 10 Explain how the study size was arrived 
at 
Methods – Selection of Genetic Variants 
Related to Cardiometabolic Traits and 
Schizophrenia – Paragraph 1; S1 
Methods 
Quantitative variables 11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which groupings 
were chosen and why 
Methods – Statistical Analysis – 
Paragraph 1 
Statistical methods 12 (a) Describe all statistical methods, 
including those used to control for 
confounding 
Methods – Statistical Analysis – 
Paragraphs 1-2; Methods - Statistical 
Analysis – Analysis using Inflammation-
related SNPs; Methods – Statistical 
Analysis – Sensitivity Analysis – 
Adjustment for inflammation 
(b) Describe any methods used to 
examine subgroups and interactions 
Methods - Statistical Analysis – Analysis 
using Inflammation-related SNPs; 
Methods – Statistical Analysis – 
Sensitivity Analysis – Adjustment for 
inflammation 
(c) Explain how missing data were 
addressed 
N/A 
(d) Cohort study—If applicable, 
explain how loss to follow-up was 
addressed 
Case-control study—If applicable, 
explain how matching of cases and 
controls was addressed 
Cross-sectional study—If applicable, 
describe analytical methods taking 
account of sampling strategy 
N/A 
(e) Describe any sensitivity analyses Methods - Statistical Analysis – Analysis 
using Inflammation-related SNPs; 
Methods – Statistical Analysis – 
Sensitivity Analysis – Adjustment for 
inflammation 
Continued on next page  
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Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-
up, and analysed 
Methods – Paragraph 1; 
S1 Methods;  
(b) Give reasons for non-participation at each stage N/A 
(c) Consider use of a flow diagram N/A 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
S1 Methods 
(b) Indicate number of participants with missing data for each 
variable of interest 
N/A 
(c) Cohort study—Summarise follow-up time (eg, average and 
total amount) 
N/A 
Outcome data 15* Cohort study—Report numbers of outcome events or 
summary measures over time 
N/A 
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure 
Methods – Paragraph 1; 
S1 Methods;  
Cross-sectional study—Report numbers of outcome events or 
summary measures 
N/A 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
Results Table 1; 
Results Table 2; 
S1 Results; S2 
Results; S3 
Results; S4 
Results.  
 
(b) Report category boundaries when continuous variables 
were categorized 
N/A 
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Results – MR 
Analyses using 
Inflammation-
related Genetic 
Variants for IR 
and Other 
Cardiometabolic 
Traits – 
Paragraph 1; 
Results – 
Sensitivity 
Analysis: 
Adjustment for 
Inflammation – 
Paragraph 1; 
Table 2; S1-2 
Results. 
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Discussion 
Key results 18 Summarise key results with reference to study objectives Discussion – Main 
Findings - Paragraph 1 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion – Strengths 
and Limitations – 
Paragraph 2 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion – Main 
Findings – Paragraph 1; 
Discussion – 
Inflammation as a 
Common Cause for 
Schizophrenia and Insulin 
Resistance – Paragraphs 1-
6; Discussion – Additional 
Findings – Paragraphs 1-2 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
Discussion – Main 
Findings – Paragraph 1; 
Discussion – 
Inflammation as a 
Common Cause for 
Schizophrenia and Insulin 
Resistance – Paragraphs 1-
6; Discussion – Additional 
Findings – Paragraphs 1-2 
Other information 
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on 
which the present article is based 
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S1 Figure: Forest Plot Illustrating MR Analyses of Schizophrenia as Outcome using All SNPs (green) 
and Inflammation-Related SNPs (purple) 
Forest plot presents beta coefficients and 95% CIs for MR analyses between inflammation and non-
inflammation-related schizophrenia SNPs and cardiometabolic outcomes. Results are presented for IVW 
analysis HDL=High Density Lipoprotein; T2DM=Type 2 Diabetes Mellitus; BMI=Body Mass Index; 
FPG=Fasting Plasma Glucose; LDL=Low-Density Lipoprotein; HbA1C=Glycated Haemoglobin; Glucose 
Tol=Glucose Tolerance. 
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